Skip to Main Content
BLACK FRIDAY SALE

60% off Quiver Premium for new subscribers

...

Use Promo Code:

BLACKFRIDAY26
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Coya Reports $10.6 Million Third-Quarter Loss as ALSTARS Enrollment Completes

None

Coya Therapeutics (COYA) reported third-quarter 2026 collaboration revenue of $234,134 and a net loss of $10.6 million, or $0.45 per basic and diluted share. The company had $35.8 million in cash and cash equivalents as of September 30, 2026.

Coya completed enrollment in its Phase 2/3 ALSTARS trial of COYA 302 for amyotrophic lateral sclerosis, enrolling 137 participants. The company expects topline data from the trial’s 24-week double-blind treatment phase in early second-quarter 2027.

  • Research and development expense was $8.6 million, compared with $2.9 million a year earlier.
  • Collaboration revenue declined from $3.6 million in the prior-year quarter.
  • Coya plans an open-label extension for ALSTARS participants completing the 48-week study period.
  • The company expects to announce frontotemporal dementia biomarker data in the first quarter of 2027.
EARLY ACCESS
Receive COYA Data Alerts
Real-time alerts on filings, insider trades, and market signals — before everyone else.
Get Alerts →

$COYA Hedge Fund Activity

We have seen 16 institutional investors add shares of $COYA stock to their portfolio, and 23 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles